Precision CancerCare - adviser information
Offering your clients access to the latest cancer care technology
Our Precision CancerCare service, provided by Further, offers your clients, and their employees support and access to customised treatment plans, using the latest tumour profiling technology.
By understanding the genetic make-up of the cancer, Further can provide a customised treatment plan specific to the individual’s tumour molecular profile, which can potentially improve outcomes, significantly reduce negative side effects of treatment and help to improve their overall quality of life.
The service also delivers an expert clinical report which provides personalised guidance regarding cancer treatment options.
Important information
New policies or existing customers going through a rate retest, initially quoted from 1 April 2025, have access to the Precision CancerCare and Second Medical Opinion+ services provided by Further.
How will this service help my clients?
As cancer is one of the leading causes of claim for Zurich Corporate Risk, making sure your clients, and their employees, have access to the very best support is a primary focus. This service ensure that employees, with a cancer that meets the eligibility criteria, have access to the latest cancer care technology.
Precision CancerCare - key features
Following a new cancer diagnosis, support can be accessed in as little as 24 hours after registering for the service. This includes:
- Genetic testing in world leading laboratories, reviewed by precision medicine experts
- If a genetic or hereditary element to the cancer is found that could affect siblings and children, counselling and testing is offered to help them make decisions about their future health
- An Expert Clinical Report with personalised treatment options
- Navigation on clinical trials
- Understanding the genetic make-up of the cancer means a more accurate prognosis
- Co-ordination and collaboration with member’s treating clinician
- This service is available once per unique cancer diagnosis
- Access to Further's Second Medical Opinion+ service
Eligibility
In order to be eligible to access this service, the cancer must be either:
- Not responding to 1st line treatment
- Diagnosed as stage 3 or 4
- From an unknown primary source or;
- A rare form of cancer, which is defined as cancers with an incidence of <6/100,000 as per Macmillan Cancer Support
More information
You can find out more about the service in the guide below.
How do our clients access Precision CancerCare?
Further send a welcome pack directly to your clients, or if we don’t have their contact details, they’ll send the pack to you to forward onto your clients. The pack will contain details on how to access the service.
Please note: If your client’s policy documentation confirms that they have access to the Precision CancerCare service, provided by Further, they should also access the Second Medical Opinion+ service provided by Further (rather than HealthHero).
Important information
This service is not part of the insurance contract and is non-contractual. It is not provided by Zurich and can be amended or withdrawn at any time. This service is free to access.